LGD-4033 vs Melanotan II
Moderate Research vs Well Studied
monitor Mechanism-based · 51% Both LGD-4033 and Melanotan II can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
LGD-4033 Melanotan II
Weight 338.25 Da —
Half-life ~24-36 hours ~2 hours
Type Nonsteroidal selective androgen receptor modulator (C14H12F6N2O) Synthetic alpha-MSH analog
Key Benefits
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Melanotan II
01 Rapid tanning without UV exposure
02 Enhanced sexual function and libido
03 Appetite suppression
04 Improved mood via melanocortin activation
05 Photoprotection through increased melanin
Dosing Protocols
LGD-4033
5-10 mg/day / Once daily (oral)
Melanotan II
Loading: Start 0.25mg daily, increase to 0.5-1mg; Maintenance: 0.5-1mg 2-3x weekly / Loading phase: Daily for first week, then tanning maintenance 2-3x weekly or as needed for sexual enhancement
Initial loading phase 0.25mg 1x daily
Tanning maintenance 0.5-1mg 2-3x weekly
Sexual enhancement 0.5-1mg As needed
Minimal side effects 0.1-0.25mg Every other day
Photoprotection 0.5mg 2x weekly
Side Effects
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Melanotan II
Nausea (pre-treatment with antiemetics recommended)
Facial flushing
Temporary blood pressure elevation
Fatigue
Spontaneous erections
Contraindications
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
History of melanoma or dysplastic nevi
Pregnancy or breastfeeding
Cardiovascular conditions
Uncontrolled hypertension
Research Evidence
LGD-4033 Melanotan II
Status Moderate Research Well Studied
References 5 studies 4 studies
Latest 2018 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.